Table 1 Characteristics of included studies
Publication | Treatments and sample size | Endpoints | Mean age (years, ± SD) | Proportion of girls | Treatment duration | Recruiting area |
|---|---|---|---|---|---|---|
Petruk, 1988 [26] | NID = 72versus PLB = 82 | GOS,3 months | 47.1 ± 1.0 | 66.9% | 21d | UK |
Schmid-elsaesser, 2006 [27] | NID = 51versus PLB = 53 | GOS,12 months | 53.0 ± 16.0 | 58.7% | 21d | Germany |
Pickard, 1989 [28] | NID = 278versus PLB = 276 | GOS,3 months | 47.0 ± 1.0 | 60.1% | 21d | UK |
Jan, 1988 [29] | NID = 73versus PLB = 54 | GOS,14 days | 48.0 ± 0.6 | 53.5% | 7-14d | France |
Ohman, 1991 [30] | NID = 104versus PLB = 109 | GOS,21 days | 45.2 ± 11.2 | 51.4% | 21d | Finland |
Zhao, 2011 [31] | NID = 60versus FSD = 55 | GOS,1 month | 50.0 ± 11.4 | 61.2% | 14d | China |
Philippon, 1986 [32] | NID = 31versus PLB = 39 | GOS,21 days | 45.0 ± 12.9 | 57.1% | 21d | France |
Westermaier, 2010 [33] | MGS = 54versus PLB = 53 | GOS,6 months | 51.0 ± 13.0 | 38.3% | 10d | Germany |
Boet, 2005 [34] | MGS = 23versus PLB = 22 | GOS,3 months | 57.0 | 45.1% | 14d | Hong Kong, China |
Muroi, 2008 [35] | MGS = 27versus PLB = 31 | GOS,3 months | 52.8 ± 12.7 | 25.9% | 12d | Switzerland |
Vandenbergh, 2005 [36] | MGS = 122versus PLB = 127 | mRS,3 months | 54.5 ± 0.1 | 67.1% | 14d | Netherlands |
Akdemir, 2009 [37] | MGS = 40versus P = 43 | GOS,3 months | 53.7 ± 0.3 | 61.4% | 10d | Turkey |
Mees, 2012 [38] | MGS = 606versus PLB = 597 | mRS,3 months | 57.0 | 69.7% | 20d | Netherlands/Chile/UK |
Wong, 2006 [39] | MGS = 30versus PLB = 30 | GOS,6 months | 60.0 ± 2.0 | 70.0% | 14d | Hong Kong, China |
Wong, 2010 [40] | MGS = 169versus PLB = 158 | mRS,6 months | 57.0 | 63.6% | 14d | Hong Kong, China |
Hassan, 2011 [41] | MGS = 15versus PLB = 15 | GOS,3 months | 49.5 ± 0.5 | 70.0% | 14d | Egypt |
Matsuda, 2016 [42] | CTZ = 74versus PLB = 74 | GOS,3 months | 58.5 ± 12.0 | 67.6% | 14d | Japan |
Senbokuya, 2013 [43] | CTZ = 54versus PLB = 55 | GOS,3 months | 60.7 ± 12.6 | 62.4% | 14d | Japan |
Suzuki, 2011 [44] | CTZ = 49versus PLB = 51 | mRS,14 days | 63.0 ± 13.5 | 76.0% | 14d | Japan |
Yoshimoto, 2009 [45] | CTZ = 26versus PLB = 24 | mRS,1 month | 59.0 ± 1.0 | 74.0% | 14d | Japan |
Macdonald, 2008 [46] | CST = 107versus PLB = 96 | GOSE,3 months | 51 ± 10.5 | 73.9% | 14d | 11 countries in Europe |
Macdonald, 2011 [47] | CST = 764versus PLB = 383 | GOSE,3 months | 51.7 ± 11.0 | 67.6% | 14d | 27 countries worldwide |
Macdonald, 2012 [48] | CST = 181versus PLB = 172 | GOSE,3 months | 53.0 ± 1.0 | 70.2% | 14d | 27 countries worldwide |
Fujimura, 2017 [49] | CST = 52versus PLB = 55 | GOSE,3 months | 55.2 ± 11.2 | 60.0% | 14d | Japan/Korea |
Shibuya, 1992 [50] | FSD = 131versus PLB = 136 | GOS,1 month | 55.0 ± 11.0 | 56.2% | 14d | Japan |
Zhao, 2006 [51] | FSD = 33versus NID = 34 | GOS,1 month | 50.1 ± 11.4 | 61.1% | 14d | China |
JingjianMA, 2009 [52] | FSD = 32versus NID = 32 | GOS,14 days | 48.5 ± 10.0 | 62.5% | 14d | China |
Tseng, 2005 [53] | ST = 40versus PLB = 40 | mRS,14 days | 52.9 ± 12.0 | 55.0% | 14d | UK |
Garg, 2013 [54] | ST = 19versus PLB = 19 | GOS,3 months | 49.1 ± 1.6 | 55.3% | 14d | India |
Naraoka, 2017 [55] | ST = 54versus PLB = 54 | GOS,3 months | 56.5 ± 1.5 | 68.5% | 14d | Japan |
Vergouwen, 2009 [56] | ST = 1 6versus PLB = 16 | GOS,3 months | 53.5 ± 0.5 | 62.5% | 14d | Netherlands |
Chou, 2008 [57] | ST = 19versus PLB = 20 | mRS,21 days | 53.1 ± 14.6 | 74.4% | 21d | USA |
Kirkpatrick, 2014 [58] | ST = 379versus PLB = 403 | mRS,6 months | 50.0 ± 9.7 | 62.7% | 21d | UK/Other countries |
Haley, 1993 [59] | NCD = 447versus PLB = 455 | GOS,3 months | 49.9 ± 14.0 | 63.8% | 14d | USA/ Canada |
Barth, 2006 [60] | NCD = 12versus PLB = 12 | mRS,12 months | 52.5 ± 7.1 | 27.0% | 14d | Germany |
Haley, 1995 [61] | TZD = 61versus PLB = 42 | GOS,3 months | 50.2 ± 14.0 | 61.2% | 21d | Canada |
Kassell, 1996 [62] | TZD = 251versus PLB = 256 | GOS,3 months | 50.1 ± 13.4 | 64.5% | 10d | Europe/Australia/New Zealand |
Haley, 1997 [63] | TZD = 300versus PLB = 299 | GOS,3 months | 51.0 ± 13.1 | 68.5% | 10d | USA |
Lanzino, 1999 [64] | TZD = 405versus PLB = 414 | GOS,3 months | 53.0 | 100.0% | 10d | Europe/Australia/New Zealand/South Africa |
Springborg, 2007 [65] | EPO = 24versus PLB = 30 | GOS,6 months | 54.6 ± 11.3 | 72.2% | 3d | Denmark |
Nakagawa, 2016 [66] | ω-3FA = 55versus PLB = 45 | mRS,3 months | 62.2 ± 2 | 52.4% | 76d | Japan |
Siironen, 2003 [67] | HPN = 85versus PLB = 85 | GOS,3 months | 49.9 ± 1.4 | 51.2% | 10d | Finland |
Etminan, 2013 [68] | rt-PA = 30versus PLB = 30 | GOS,3 months | 56.1 ± 10.4 | 63.3% | 11d | Germany |
Gomis, 2010 [69] | MPN = 49versus PLB = 46 | GOS,12 months | 49.8 ± 13.2 | 63.2% | 21d | France |